

Launch of Neupro® — the first dopamine agonist patch — provides new approach to treatment of Parkinson's disease

Patients with early-stage Parkinson's disease could benefit from an innovative treatment launched in the UK on 5 April 2006. Neupro® (rotigotine transdermal patch), developed by Schwarz Pharma, combines a new dopamine agonist, rotigotine, with the benefits of a transdermal delivery system.

The transdermal delivery system of Neupro® provides consistent and continuous drug delivery over 24 hours and proven efficacy in early Parkinson's disease. The patient needs to wear a patch, which is applied once a day. Drug delivery via a transdermal patch eliminates the



Daily activities, such as shaving, can continue as normal when wearing the Neupro® patch.

peaks and troughs in drug levels associated with oral treatment that can lead to fluctuations in symptom control. Once-a-day dosing is likely to be more convenient for patients than taking tablets several times a day.

The new dopamine agonist, rotigotine – the active ingredient in Neupro® – has a receptor-binding profile that is very similar to naturally occurring dopamine, and is a new and innovative treatment option for early-stage Parkinson's disease.

For more information see www.schwarzpharma.co.uk

Abilify® (Aripiprazole) has superior effectiveness and improved metabolic profile compared to other standard-of-care antipsychotics

New data from the STAR (Schizophrenia Trial of Aripiprazole) study show that Abilify® (aripiprazole) demonstrated superior effectiveness to Standard-Of-Care (SOC; olanzapine, quetiapine, risperidone), as measured by the Investigator Assessment Questionnaire (IAQ) total score, which is based on 10 different factors. In this study, people with schizophrenia treated with aripiprazole experienced significantly less weight gain, and improved lipid profiles, sexual


function and overall quality of life (QoL) compared to those treated with SOC antipsychotics. Overall, significantly more patients in the aripiprazole group than the SOC group whose symptoms were not controlled by their previous antipsychotic or who experienced tolerability issues, reported that aripiprazole was "much better" than their prior medication.

For further information contact aviva.kessler@popewoodhead.com



Dr Helen Millar,
STAR study
investigator.

Textbook of Neural Repair and Rehabilitation



In two freestanding but linked volumes, Textbook of Neural Repair and Rehabilitation provides comprehensive coverage of the science and practice of neurological rehabilitation. Volume One, Neural Repair and Plasticity, covers the basic sciences relevant to recovery of function following injury to the nervous system, reviewing plasticity in the normal CNS, mechanisms of neuronal death, axonal regeneration, stem cell biology and current research strategies. Volume Two, Medical Neurorehabilitation, provides authoritative guidelines on the management of disabling symptoms and describes comprehensive rehabilitation approaches for the major categories of disabling neurological disorders. Edited and written by leading international authorities from the neurosciences and clinical neurorehabilitation, the two-volume set is an essential resource for rehabilitation professionals and a comprehensive reference for all scientists and clinicians in the field.

Textbook of Neural Repair and Rehabilitation:

978 0 521 85641 6, Volume 1: Neural Repair and Plasticity - £110.00

978 0 521 85642 3, Volume 2: Medical Neurorehabilitation - £110.00

978 0 521 83639 5, 2 volume set - £180.00 Save £60.00!



For further information contact Cherrill Richardson,
Cambridge University Press, Email. crichardson@cambridge.org

New Epilepsy DVDs from the National Society for Epilepsy

The NSE is producing two new DVDs:

manyLives: a 3-disc DVD educational programme for professionals involved in the treatment and management of epilepsy. It costs £120 including p&p and includes:

- An introduction to managing the epilepsies presented by Prof John Duncan
- 45 minute programme on the general principles of managing epilepsy
- oneLife - living with epilepsy: a 40 minute feature for people with epilepsy
- Printable tools including templates for referral letters and epilepsy audit tools
- Interviews with leading professionals on specific areas of care within epilepsy, including: women with epilepsy, epilepsy in later life, epilepsy in childhood and epilepsy and learning disabilities.



oneLife: for anyone who has been affected by epilepsy. It features four adults talking about how epilepsy has affected their lives and what having epilepsy means to them. It will be available to buy in either DVD or VHS format, for £12, including p&p.

For more information contact Amanda Cleaver,
National Society for Epilepsy, Tel. 01494 601404 (direct line),
Email. amanda.cleaver@epilepsynse.org.uk